Drugs associated with good response in progressing patients for whom R-CHOP chemotherapy failed
| Reference . | Drug . | MOA . | No. of patients/cell lines . | ORR . | PFS . | Toxicity . |
|---|---|---|---|---|---|---|
| 124 | Valproic acid | HDAC inhibitors | Cell lines | Increased apoptosis and DNA damage | ||
| 125 | OTX015 | Bromodomain and extraterminal inhibitor | 22 (17 evaluable) | 3 patients (1 of 5 patients was MYC positive) | NA | Thrombocytopenia |
| 126 | Imexon | Pro-oxidant molecule | 5 | 2 patients | 3 mo | Anemia, neutropenia |
| 127 | Vatalanib | VEGFR inhibitor | 18 | 1 CR | NA | Thrombocytopenia |
| 128 | Sunitinib | VEGFR kinase inhibitor | 17 | None | NA | Neutropenia, thrombocytopenia |
| 129 | Lenalidomide | Immunomodulatory agent, antiproliferative and antiangiogenic effects, others | ||||
| 130 | Coltuximab ravtansine | Anti-CD19 ADC | 45 | 31% | 3.9 mo | Gastrointestinal disorders, anemia |
| 131 | Pixantrone | Aza-anthracenedione | 92 | 24% (10% CR); less in refractory patients | 2 mo | Infections |
| 132 | Fostamatinib | Spleen tyrosine kinase inhibitor | 68 | 3% | Diarrhea, nausea, fatigue | |
| 133 | Rentuximab vedotin | Anti-CD30 ADC (in patients with CD30+) | 49 | 44% (17% CR) | DOR, 5.6 mo | Neutropenia |
| 134 | Cerdulatinib | Dual SYK/JAK kinase inhibitor | Cell lines | Induction of apoptosis, inhibition of RB phosphorylation | ||
| 135 | Obinutuzumab | Type II, glycoengineered humanized anti-CD20 monoclonal antibody | 25 | 32% | 2.7 mo | Infusion-related reactions |
| 136 | Anti-CD22 and anti-79b ADC | Antibody-drug conjugates linked to MMAE | ||||
| 137 | Belinostat | HDAC inhibitor | 22 | 10.5% | 2.1 mo | Well tolerated |
| 138 | Blinatumomab | Bi-specific T-cell engager | 21 | 43% (19% CR) | 3.7 mo | Tremor, pyrexia, fatigue, edema |
| 139 | Ibrutinib | Inhibitor of BCR signaling | 80 | 37% in ABC and 5% in GCB lymphoma | 2 mo in ABC and 1.3 mo in GCB lymphoma | NA |
| 140 | Small mimetics | Mediators of BCR-dependent NF-kB activity (cIAP1/cIAP2) | Cell lines | IKK activation, suppression of NF-kB in ABC cell lines | ||
| 23 | Venetoclax | BCL2 inhibitor | ||||
| 141 | Dacetuzumab | Anti-CD40 monoclonal antibody | 46 | 9% | 36 d | Fatigue, chills, fever |
| 142 | CC-122 | Pleiotropic pathway modifier promoting degradation of Aiolos and Ikaros in mice |
| Reference . | Drug . | MOA . | No. of patients/cell lines . | ORR . | PFS . | Toxicity . |
|---|---|---|---|---|---|---|
| 124 | Valproic acid | HDAC inhibitors | Cell lines | Increased apoptosis and DNA damage | ||
| 125 | OTX015 | Bromodomain and extraterminal inhibitor | 22 (17 evaluable) | 3 patients (1 of 5 patients was MYC positive) | NA | Thrombocytopenia |
| 126 | Imexon | Pro-oxidant molecule | 5 | 2 patients | 3 mo | Anemia, neutropenia |
| 127 | Vatalanib | VEGFR inhibitor | 18 | 1 CR | NA | Thrombocytopenia |
| 128 | Sunitinib | VEGFR kinase inhibitor | 17 | None | NA | Neutropenia, thrombocytopenia |
| 129 | Lenalidomide | Immunomodulatory agent, antiproliferative and antiangiogenic effects, others | ||||
| 130 | Coltuximab ravtansine | Anti-CD19 ADC | 45 | 31% | 3.9 mo | Gastrointestinal disorders, anemia |
| 131 | Pixantrone | Aza-anthracenedione | 92 | 24% (10% CR); less in refractory patients | 2 mo | Infections |
| 132 | Fostamatinib | Spleen tyrosine kinase inhibitor | 68 | 3% | Diarrhea, nausea, fatigue | |
| 133 | Rentuximab vedotin | Anti-CD30 ADC (in patients with CD30+) | 49 | 44% (17% CR) | DOR, 5.6 mo | Neutropenia |
| 134 | Cerdulatinib | Dual SYK/JAK kinase inhibitor | Cell lines | Induction of apoptosis, inhibition of RB phosphorylation | ||
| 135 | Obinutuzumab | Type II, glycoengineered humanized anti-CD20 monoclonal antibody | 25 | 32% | 2.7 mo | Infusion-related reactions |
| 136 | Anti-CD22 and anti-79b ADC | Antibody-drug conjugates linked to MMAE | ||||
| 137 | Belinostat | HDAC inhibitor | 22 | 10.5% | 2.1 mo | Well tolerated |
| 138 | Blinatumomab | Bi-specific T-cell engager | 21 | 43% (19% CR) | 3.7 mo | Tremor, pyrexia, fatigue, edema |
| 139 | Ibrutinib | Inhibitor of BCR signaling | 80 | 37% in ABC and 5% in GCB lymphoma | 2 mo in ABC and 1.3 mo in GCB lymphoma | NA |
| 140 | Small mimetics | Mediators of BCR-dependent NF-kB activity (cIAP1/cIAP2) | Cell lines | IKK activation, suppression of NF-kB in ABC cell lines | ||
| 23 | Venetoclax | BCL2 inhibitor | ||||
| 141 | Dacetuzumab | Anti-CD40 monoclonal antibody | 46 | 9% | 36 d | Fatigue, chills, fever |
| 142 | CC-122 | Pleiotropic pathway modifier promoting degradation of Aiolos and Ikaros in mice |
ADC, antibody-drug conjugate; cIAP1, cellular inhibitor of apoptosis protein-1; DOR, duration of response HDAC, histone deacetylase; IKK, IκB kinase; MMAE, monomethyl auristatin E; MOA, mechanism of action; NA, not applicable; ORR, overall response rate; RB, retinoblastoma protein; VEGFR, vascular endothelial growth factor receptor.